---
source_pdf: "https://drive.google.com/file/d/1Q1WRDOvo3isUBzfXUTZ9Hz7Ot4pGp1dGB_VLw5kgNYM/view"
drive_folder: "Research"
type: research

ingested: 2025-12-27
original_filename: "Investors Master HA full"
---

> **Original:** [View Original PDF](https://drive.google.com/file/d/1Q1WRDOvo3isUBzfXUTZ9Hz7Ot4pGp1dGB_VLw5kgNYM/view)

Getting on a Specialty Treatment is

● Scary

● Complicated

● Expensive

● Confusing

How much is it

going to cost?

I haven’t gotten a  call yet … should  I call my doctor?

Where was my  prescription  sent?

Do I have to pick  up my

prescription?

Incoming Call:

Where is my  prescription?

Unknown  Number

For Specialty Treatments, the Rx is Just the Beginning…

The Specialty Drug Category: An underserved behemoth

Complex or Rare Chronic Conditions:  cancer, rheumatoid arthritis, hemophilia,

$535B Annual Drug Spending

H.I.V., psoriasis, inflammatory bowel  disease and hepatitis C

� High Cost

Number of Rx  98%

Total Spending Specialty Spending 45%

✋ High Touch

� High

Complexity

TRADITIONAL /  RETAIL DRUG PRESCRIPTIONS

2% SPECIALTY

TRADITIONAL  DRUG Rx

55% (2021)

27% (2010)

$263B SPECIALTY

DRUG

SPENDING

$76B LOST REVENUE OPPORTUNITY

$76B = 27% patient drop-off related to Access challenges

RxNon Commercial

Copay Pre-Rx Specialty

Assistance Hub Adherence  Patient

Marketing

online  communities

Pharmacy CPR+

Pharmacy

Pharma’s

Patient Services

Support

$76B LOST REVENUE OPPORTUNITY

4

Pharmas’ problem: Patient drop-off related to Access challenges

Pre-Rx

Rx NCP Patient

Marketing

online

communities

Specialty Pharmacy

CPR+

Copay

Pharma’s

Patient Services

Assistance Hub Adherence  Support

New entrants emerge, but the silos remain

5

Instead of yet-another siloed app or portal, we built: Patient Journey Gateway

Simplifying Patients’ Lives

Our Patient Journey Gateway simplifies the path to therapy across silos

Pre-Rx

Rx NCP Patient

Adherence

Marketing

Specialty Pharmacy

Copay

Assistance Hub

Support

online

communities

CPR+

Plugin TCPA

Pharma’s

Patient Services

Patient Services CRM / Salesforce

Patient Referrals Patient Referrals

API

API API eFax API API Patient Journey Gateway

Patient Journey Gateway

Patient Journey Gateway

API

TCPA & HIPAA

Free Drug

Copay

Prior Auth

PAP

Lab Results

Eligibility MIRF plugin PQC plugin HIPAA Consent Consent

3rd Party Plugins

Gateway

Eligibility

updates

enrollment

Plugin

Modules Patient Experience Library

7

2 Drug Segments: Specialty Lite vs Rare / Orphan Specialty Lite

Rare / Orphan

High Rx volume x Lower WAC

Low Rx volume x High WAC

WAC / Drug Price

$30k-50k / patient / year $100K - $500K / patient / year

5,000 -

80,000

per patient per year

100 - 2,000

treated

population

treated population

✔ Higher enrollment completion ⇒ More patients get on therapy  ✔ Faster therapy enrollment ⇒ Patients get on therapy sooner

Pricing = Setup fee + Recurring license fee + per-subscriber (recurring)

8

Results Across Drug Categories

Rare Disease

Complex therapy

● Multiple caregivers

● Multiple pediatric patients

● Dosage changes

● Weight checks

● Full hub enrollment, financial support +  automatic entry into PAP review

● Multiple insurance types; needed to include  state Medicaid

Chronic, Oral

Specialty Lite

● Real-time benefit check  ● SMS adherence

● copay card

● consent

● Self-enrollment

Oncology, HCP administered Copay, PAP

● Full hub enrollment, financial support +  automatic entry into PAP review

● Multiple status update for pharmacy  and shipment location

● Reminder messages to complete  registration

● App for educational materials &  updates

49 days faster time to therapy  ○ 14 days with HelpAround vs 63 days for  competitor product without HA

6 minute avg enrollment

with HelpAround (vs 7-10d industry standard)

5x faster time to first fill 38% faster time to therapy  ○ 15.6 days vs 9 d with HelpAround

90 seconds to receiving a copay card 2 minute avg enrollment

84% enrollment completion with HelpAround

93% enrollment completion  with HelpAround

80% vs 66% enrollment completion

$475M in drug revenue enabled 30:1 ROI 14:1 ROI

9

Current Book of Business: Evolution from pilots to commercial sales

The programs below have all been signed. ACV trajectory assumes no scope changes and no changes to current growth rate

Newly launched

2022

programs,

ACV growth =

Rare Pediatric: UCB Fintepla

pre ramp-up

Lite segment  (Migraine):

2022

** Committed ARR from Signed Contracts

program ramping up

Rare Orphan: Mirum Livmarli

Volume-driven ACV

Pricing validation ACV = $300K

Early pilots

ACV <$50K

2021 2020

10

The Future: No-code, Patient Journey Builder

Patient

Journey

Edit every page of the journey Prepare for MLR review & version control

Organize elements

From logos to images to textDrag and drop interface Easy for non-technical users

Network GTM: Build the rails ⇒ accelerate land grab ⇒ monetize HCP Writes Specialty Rx

Patient Assistance

ePrescribe network: 90% market share

HUB

Physician network; Acquired by McKesson

Prior Authorization network;

acquired for $1.2B

TOTAL $5B Market Cap

Copay Specialty Pharmacy

15

Connected Across the industry

Connected Discussions

HUBS

CO-PAY SPECIALTY PHARMACIES

PATIENT ASSISTANCE

80+ others...

DATA AGGREGATORS

SYSTEMS

INTEGRATORS

REMS

ADMINISTRATION

COMMERCIALIZATION SERVICES

16

Competitive Landscape: Pharma Patient Services Platforms

Siloed patient-facing platforms like adherence apps and portals end up adding friction to patient onboarding. HelpAround removes friction by connecting services and vendors across the entire patient journey, behind the scenes.

WHITE LABEL,

VENDOR-AGNOSTIC

Enrollment only

Adherence only

POINT

SOLUTIONS

(enrollment /

Patient Journey Gateway

CONNECTED ACROSS THE PATIENT JOURNEY

adherence)

Adherence only

BRANDED /

VENDOR-SPECIFIC

17

CONSUMER FACING APP

When patients drop-off, everyone loses

27% of patient drop-off is related to Access challenges

● The Patient loses doesn’t get access to the treatment ● The Pharma loses doesn’t provide the medication

● Specialty Pharmacies don’t get to dispense

● Payers & Employers increased cost of hospitalization

Patient Pharma

Pharma Only

Specialty  Pharmacy

Payer

$8.2B

=

total addressable market

7M patients x $98 per month x 12 months U.S. Specialty Patients demonstrated pricing

No one knows Rx networks like we do

Yishai Knobel

Founder & CEO

MANAGEMENT

Dan Bar Yehuda, PhD

VP R&D

BOARD OF DIRECTORS

Dr. Raeanna Lewarne, PharmD, VP Product

former CEOCorporate Ventures

Shlomi Aflalo Co-Founder, CTO

Harry Totonis, Board Member

Adam Fine

Harietta

Eleftherochorinou, PhD

20

Financing

$6-8M A Round USE OF FUNDS

● Breakeven in Q4, 2024

● Build commercial team of Account Execs to land and expand large  enterprise accounts

● Headcount growth over 3 years : 15 ⇒ 37 ⇒ 46 ⇒ 51

Sales & Marketing

● Hire marketing ⇒ Optimize patient inlets ● Sales & Marketing ⇒ target launch drugs earlier ● Hire biz-dev / partnerships

● Expand CSS team

COGS / Services

● Accelerate account implementation ● Hire customer support

● Hire data analyst

● SOC2 certification

Product + R&D

● Publicize “patient journey builder” toolkit ● Build self-serve partner experience

Product & Infrastructure

● Hire devs ⇒ Expand gateway APIs

G&A

● Hire Head of People

● Infrastructure for 100% distributed team

21

2022 2023 2024 2025 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4

EOY CARR

EOY 2022 $2M

EOY 2023 $4.6M

EOY 2024 $9.4M

EOY 2025 $21M

SINGLE

BRANDS

ENTERPRISE ACCOUNTS: PIPELINE + MQL

SUPPORTING HEADCOUNT:

Acadia

Trofinetide

CEMIPLIMAB

Daprodustat

CURRENT 2023 EOY TOTAL 2024 EOY TOTAL

SQL / Biz Dev (YK)

0

6

8

+1 VP Growth +1 BDR +1 AEs

+1 Sales Ops + 1 BDR

1

+1 Mkting Assoc.

+3 AEs

MQL / Marketing (DD)

+1 VP Marketing +1 Mkting Manager

3

4

COGS R&D

4 9

+2 eng

+1 proj mgr.

+2 eng.

+1 product

+1 BA

+1 Sr. pm +1 architect

+2 eng.

8

16

+1 eng

+ 1 eng.

+1 QA (eng)

+ 1 product +1 designer

+ 1 eng.

9

21

G&A

1

+1 HR +1 COO +1 full admin 4

4

37 46 +7 +2

15

+10

+5

+5

+2

51

Simplifying Patients’ Lives